Baxter Healthcare recalled 106,176 units of the CLEARLINK SYSTEM CONTINU-FLO Solution Set on August 29, 2025. The recall follows reports that the IV sets may leak, posing a high risk to patients. Healthcare providers and patients must stop using the device immediately.
IV sets may leak.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Baxter Healthcare Corporation or your healthcare provider for instructions
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is the CLEARLINK SYSTEM CONTINU-FLO Solution Set, Non-Vented, with a 0.2 Micron Filter. It features two CLEARLINK Luer Activated Valves, a Backcheck Valve, and is 104 inches long. The product code is 2C8571.
The IV solution sets may leak, which can result in serious complications for patients. This poses a high risk as it can lead to medication errors or inadequate fluid delivery.
There are no specific reported injuries or deaths associated with this recall. However, the potential for leakage presents a significant safety concern.
Patients and healthcare providers should stop using the recalled IV solution sets immediately. Follow the manufacturer's recall instructions and contact Baxter Healthcare Corporation or your healthcare provider for further instructions.
For more information, contact Baxter Healthcare Corporation. Visit their website or call their customer service for detailed instructions on returns and refunds.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.